PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad105 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Sabine Mueller und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Diffuse Intrinsic Pontine Glioma, Brain Stem Neoplasms, Glioma. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: V foundation, PNOC Foundation, Pediatric Brain Tumor Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The objective of this study was to determine the safety, tolerability, and distribution of MTX110 (aqueous panobinostat) delivered by convection-enhanced delivery (CED) in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) who completed focal radiation therapy (RT).
Methods
Patients with DIPG (2–21 years) were enrolled after RT. CED of MTX110 combined with gadoteridol was completed across 7 dose levels (DL) (30–90 µM; volumes ranging from 3 mL to 2 consecutive doses of 6 mL). An accelerated dose escalation design was used. Distribution of infusate was monitored with real-time MR imaging. Repeat CED was performed every 4–8 weeks. Quality-of-life (QoL) assessments were obtained at baseline, every 3 months on therapy, and end of therapy.
Results
Between May 2018 and March 2020, 7 patients who received a total of 48 CED infusions, were enrolled (median age 8 years, range 5–21). Three patients experienced dose-limited toxicities. Four grade 3 treatment-related adverse events were observed. Most toxicities were transient new or worsening neurologic function. Median overall survival (OS) was 26.1 months (95% confidence interval: 14.8–not reached). Progression-free survival was 4–14 months (median, 7). Cumulative percentage of tumor coverage for combined CED infusions per patient ranged from 35.6% to 81.0%. Increased CED infusions were negatively associated with self-reported QoL assessments.
Conclusion
Repeat CED of MTX110 with real-time imaging with gadoteridol is tolerable for patients with DIPG. Median OS of 26.1 months compares favorably with historical data for children with DIPG. The results support further investigation of this strategy in a larger cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
- Department of Pediatrics, University of California, San Francisco, San Francisco, California, USA.
- Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
- Department of Pediatrics, University of Zurich, Zurich, Switzerland.
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Sabine Mueller, Cassie Kline, Schuyler Stoller, Shannon Lundy, Alyssa T Reddy, Anu Banerjee, Carly Hoffman, Javad Nazarian, Annette M Molinaro, Michael Prados, Javier E Villanueva-Meyer, Nalin Gupta
Förderung
- V foundation
- PNOC Foundation
- Pediatric Brain Tumor Foundation
- DIPG Collaborative Foundation
Zitieren
APA
Mueller, S., Kline, C., Stoller, S., Lundy, S., Christopher, L., Reddy, A. T., Banerjee, A., Cooney, T. M., Raber, S., Hoffman, C., Luks, T., Wembacher-Schroeder, E., Lummel, N., Zhang, Y., Bonner, E. R., Nazarian, J., Molinaro, A. M., Prados, M., Villanueva-Meyer, J. E., & Gupta, N. (2023). PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad105
Vancouver
Mueller S, Kline C, Stoller S, Lundy S, Christopher L, Reddy AT, et al. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad105
BibTeX
@article{Mueller2023,
author = {Mueller, Sabine and Kline, Cassie and Stoller, Schuyler and Lundy, Shannon and Christopher, Lauren and Reddy, Alyssa T and Banerjee, Anu and Cooney, Tabitha M and Raber, Shannon and Hoffman, Carly and Luks, Tracy and Wembacher-Schroeder, Eva and Lummel, Nina and Zhang, Yalan and Bonner, Erin R and Nazarian, Javad and Molinaro, Annette M and Prados, Michael and Villanueva-Meyer, Javier E and Gupta, Nalin},
title = {PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad105}
}
EUVIMED